GlassScriptPhysician profile
Thomas Eugene Collins
NPI 1194750083
$1,970.08
in general payments reported to CMS, 2019-2025
25 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2022: $41.45 · 2023: $117 · 2024: $837 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Travel and Lodging: $523 · Education: $33.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.71 |
| Travel and Lodging | $523.25 |
| Education | $33.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $523.25 | 2024 | |
| Medtronic, INC. | $159.03 | 2024-2025 | Signia |
| Werfen USA LLC | $147.67 | 2025 | |
| Intercept Pharmaceuticals, INC. | $141.08 | 2019-2023 | Ocaliva |
| Boston Scientific Corporation | $128.01 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Dova Pharmaceuticals | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.63 | 2019 | |
| Gilead Sciences, INC. | $105.00 | 2019 | |
| Madrigal Pharmaceuticals | $64.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Astellas Pharma US INC | $55.58 | 2022-2023 | Cresemba |
| Kci USA, INC. | $52.72 | 2023 | Prevena |
| Integra Lifesciences Corporation | $34.29 | 2023 | Codman Certas, Codman Hakim, Cusa Clarity |
| Veloxis Pharmaceuticals, INC. | $31.98 | 2024 | Envarsus |
| Octapharma USA, INC. | $31.39 | 2025 | Fibryga |
| Healthmyne, INC. | $28.64 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $27.94 | 2024 | Exparel |
| Ipsen Biopharmaceuticals, INC | $26.63 | 2025 | Bylvay |
| Innovation Technologies INC | $25.84 | 2024 | Irrisept |
| Merck Sharp & Dohme LLC | $24.45 | 2025 | Prevymis |
| Shionogi INC | $19.97 | 2019 | |
| Biocompatibles, INC. | $19.43 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.39 | 2024 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.62 | 2025 | Livtencity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.41 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.